The proportion of the population over the age of 65 is growing the most rapidly due to the longevity revolution. Frailty is prevalent in this age group and strongly associated with disability and hospitalization, having a significant impact on the costs of health and social care. New effective interventions to delay or reverse frailty are urgently required. Geroprotectors are a new class of drugs, which target fundamental mechanisms of ageing and show promise in delaying the onset of or boosting resilience in frail older people. However, there are challenges to their clinical translation. Here we review the literature for evidence that frailty can be delayed or reversed and geroprotectors can improve frailty in murine models and in patients. We will then discuss the challenges, which make their clinical testing complex and propose potential options for moving forward.
Geroprotectors: A role in the treatment of frailty.
A. Trendelenburg,Ariane C. Scheuren,P. Potter,R. Müller,I. Bellantuono
Published 2019 in Mechanisms of Ageing and Development
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Mechanisms of Ageing and Development
- Publication date
2019-06-01
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-40 of 40 citing papers · Page 1 of 1